Thiago Gonçalves Guimarães
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thiago Gonçalves Guimarães has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Fernando Kok
Department of Neurology, Neurogenetics Center University of São Paulo São Paulo Brazil
3 shared publicationsFernando Freua
Neurogenetics Center, Department of Neurology, University of Sao Paulo, Sao Paulo, Brazil
2 shared publicationsPedro Braga-Neto
Division of Neurology, Federal University of Ceara, Fortaleza, Brazil
2 shared publications- Rubens Gisbert Cury
Movement Disorders Center, Department of Neurology, School of Medicine University of São Paulo São Paulo Brazil
2 shared publications Anderson R B Paiva
Neurogenetics Center, Department of Neurology, University of Sao Paulo, Sao Paulo, Brazil
1 shared publicationAnderson Rodrigues Brandão Paiva
University of São Paulo
1 shared publication
Latest Publications
- 7 July 2026
- Published by Wiley in Movement Disorders Clinical Practice
Novel Homozygous Pathogenic Variant in DNAJC6 Causes Rapid Progressive Parkinsonism
Background: Biallelic variants in DNAJC6 cause PARK‐ DNAJC6 (historically referred to as PARK19), a rare autosomal recessive juvenile‐onset dystonia‐parkinsonism syndrome. Neurodevelopmental delay or regression, epilepsy, movement disorders, and psychiatric symptoms are also present. Progression is fast with frequent bulbar, gastrointestinal involvement and early loss of ambulation. Cases: We report two siblings (17 and 14 years) harboring a novel homozygous nonsense variant in DNAJC6 , p.Cys325*, not previously described in the medical literature and absent from population databases. The variant is predicted to truncate the protein, supporting a loss‐of‐function mechanism consistent with the gene's disease biology. Both patients exhibited developmental regression, parkinsonism with dystonia, cognitive decline, dysphagia, and marked sialorrhea, with severe, accelerated functional deterioration. Levodopa produced only mild benefit; in the older sibling, dose escalation provoked an adverse reaction with sustained upgaze/ophthalmoparesis, opisthotonus, and hypertension. Literature review: We found 23 previously reported DNAJC6 patients, most with early‐onset parkinsonism with variable levodopa responsiveness, frequent developmental and psychiatric comorbidity, and prominent bulbar features. Conclusions: The novel DNAJC6 p.Cys325* variant is associated with severe, early‐onset parkinsonism and developmental regression. DNAJC6 should be considered in children and adolescents presenting with parkinsonism plus neurodevelopmental decline, particularly when levodopa benefit is modest, and dose‐related adverse motor crises occur.
- 7 July 2026
- Published by Wiley in Movement Disorders Clinical Practice
Novel Homozygous Pathogenic Variant in DNAJC6 Causes Rapid Progressive Parkinsonism
Background: Biallelic variants in DNAJC6 cause PARK‐ DNAJC6 (historically referred to as PARK19), a rare autosomal recessive juvenile‐onset dystonia‐parkinsonism syndrome. Neurodevelopmental delay or regression, epilepsy, movement disorders, and psychiatric symptoms are also present. Progression is fast with frequent bulbar, gastrointestinal involvement and early loss of ambulation. Cases: We report two siblings (17 and 14 years) harboring a novel homozygous nonsense variant in DNAJC6 , p.Cys325*, not previously described in the medical literature and absent from population databases. The variant is predicted to truncate the protein, supporting a loss‐of‐function mechanism consistent with the gene's disease biology. Both patients exhibited developmental regression, parkinsonism with dystonia, cognitive decline, dysphagia, and marked sialorrhea, with severe, accelerated functional deterioration. Levodopa produced only mild benefit; in the older sibling, dose escalation provoked an adverse reaction with sustained upgaze/ophthalmoparesis, opisthotonus, and hypertension. Literature review: We found 23 previously reported DNAJC6 patients, most with early‐onset parkinsonism with variable levodopa responsiveness, frequent developmental and psychiatric comorbidity, and prominent bulbar features. Conclusions: The novel DNAJC6 p.Cys325* variant is associated with severe, early‐onset parkinsonism and developmental regression. DNAJC6 should be considered in children and adolescents presenting with parkinsonism plus neurodevelopmental decline, particularly when levodopa benefit is modest, and dose‐related adverse motor crises occur.
- 9 February 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (5) , 677-680
Improvement of Motor Function in SLC39A8‐Related Ataxia Through Manganese Supplementation: A Therapeutic Insight
- 9 February 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 12 (5) , 677-680
Improvement of Motor Function in SLC39A8‐Related Ataxia Through Manganese Supplementation: A Therapeutic Insight
- Open Access
- 26 June 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (7) , 638
New Perspectives of Deep Brain Stimulation Indications for Parkinson’s Disease: A Critical Review
Deep Brain Stimulation (DBS) is an effective treatment option for patients with dopaminergic complications of Parkinson’s disease (PD) and drug-refractory PD tremor. However, DBS and its indications can be challenging, and they are not often debated in the medical community. Through a critical narrative review, the objective of this paper is to improve the comprehension of DBS indications and help to solve the puzzle that this process can be. Proper patient selection is the first step for a good surgical outcome. In this review, then, relevant considerations are discussed, involving PD genes, PD phenotypes, indications of early stages, non-motor symptoms, neuroimaging predictors, comorbidities, and age. Individualized approaches are encouraged, including clinical and radiological factors. Social support during the whole follow-up and expectations alignment are necessary through this process and are also debated.
- 26 June 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (7) , 638
Open AccessNew Perspectives of Deep Brain Stimulation Indications for Parkinson’s Disease: A Critical Review
Deep Brain Stimulation (DBS) is an effective treatment option for patients with dopaminergic complications of Parkinson’s disease (PD) and drug-refractory PD tremor. However, DBS and its indications can be challenging, and they are not often debated in the medical community. Through a critical narrative review, the objective of this paper is to improve the comprehension of DBS indications and help to solve the puzzle that this process can be. Proper patient selection is the first step for a good surgical outcome. In this review, then, relevant considerations are discussed, involving PD genes, PD phenotypes, indications of early stages, non-motor symptoms, neuroimaging predictors, comorbidities, and age. Individualized approaches are encouraged, including clinical and radiological factors. Social support during the whole follow-up and expectations alignment are necessary through this process and are also debated.
- Open Access
- 23 May 2024
- Published by Springer Nature in BMC Neurology
- Vol. 24 (1) , 1-4
Myoclonus improvement after seizures in progressive myoclonic epilepsy type 7: a case report
Background: Progressive Myoclonic Epilepsy (PME) is a group of rare diseases that are difficult to differentiate from one another based on phenotypical characteristics. Case report: We report a case of PME type 7 due to a pathogenic variant in KCNC1 with myoclonus improvement after epileptic seizures. Discussion: Myoclonus improvement after seizures may be a clue to the diagnosis of Progressive Myoclonic Epilepsy type 7.
- 23 May 2024
- Published by Springer Nature in BMC Neurology
- Vol. 24 (1) , 1-4
Open AccessMyoclonus improvement after seizures in progressive myoclonic epilepsy type 7: a case report
Background: Progressive Myoclonic Epilepsy (PME) is a group of rare diseases that are difficult to differentiate from one another based on phenotypical characteristics. Case report: We report a case of PME type 7 due to a pathogenic variant in KCNC1 with myoclonus improvement after epileptic seizures. Discussion: Myoclonus improvement after seizures may be a clue to the diagnosis of Progressive Myoclonic Epilepsy type 7.
- Open Access
- 2 January 2024
- Published by Springer Nature in Research Square
Myoclonus improvement after seizures in progressive myoclonic epilepsy type 7: a case report
Background: Progressive Myoclonic Epilepsy (PME) is a group of rare diseases that are difficult to differentiate from one another based on phenotypical characteristics. Case Report: We report a case of PME type 7 due to a pathogenic variant in KCNC1 with myoclonus improvement after epileptic seizures. Discussion: Myoclonus improvement after seizures may be a clue to the diagnosis of Progressive Myoclonic Epilepsy type 7.
- 2 January 2024
- Published by Springer Nature in Research Square
Open AccessMyoclonus improvement after seizures in progressive myoclonic epilepsy type 7: a case report
Background: Progressive Myoclonic Epilepsy (PME) is a group of rare diseases that are difficult to differentiate from one another based on phenotypical characteristics. Case Report: We report a case of PME type 7 due to a pathogenic variant in KCNC1 with myoclonus improvement after epileptic seizures. Discussion: Myoclonus improvement after seizures may be a clue to the diagnosis of Progressive Myoclonic Epilepsy type 7.
- 14 June 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 98 (24) , 1031-1032
Teaching Video NeuroImage: Peculiar Hobby Horse Gait in Huntington Disease–like 2
- 14 June 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 98 (24) , 1031-1032
Teaching Video NeuroImage: Peculiar Hobby Horse Gait in Huntington Disease–like 2
- 15 February 2022
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 12 (2) , 737-741
Troubleshooting Gait Problems in Parkinson’s Disease Patients with Subthalamic Nucleus Deep Brain Stimulation
Subthalamic nucleus deep brain stimulation (STN DBS) is an established therapy for a subset of patients with Parkinson’s disease, and the adjustment of DBS parameters is typically guided by the patients’ rigidity and tremor. Although these cardinal symptoms remain relatively stable over time, progressive worsening of axial symptoms compromise motor function and quality of life. Because many patients report improvements in their global mobility after gait improvement, we have been adjusting DBS parameters during the long-term after surgery based on gait analysis. Here, we describe a practical strategy for troubleshooting gait problems in PD DBS patients by revising stimulation parameters through “hands-on” programming, which can be a useful alternative approach for improving patients’ outcomes after STN DBS.
- 15 February 2022
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 12 (2) , 737-741
Troubleshooting Gait Problems in Parkinson’s Disease Patients with Subthalamic Nucleus Deep Brain Stimulation
Subthalamic nucleus deep brain stimulation (STN DBS) is an established therapy for a subset of patients with Parkinson’s disease, and the adjustment of DBS parameters is typically guided by the patients’ rigidity and tremor. Although these cardinal symptoms remain relatively stable over time, progressive worsening of axial symptoms compromise motor function and quality of life. Because many patients report improvements in their global mobility after gait improvement, we have been adjusting DBS parameters during the long-term after surgery based on gait analysis. Here, we describe a practical strategy for troubleshooting gait problems in PD DBS patients by revising stimulation parameters through “hands-on” programming, which can be a useful alternative approach for improving patients’ outcomes after STN DBS.
- Open Access
- 17 January 2022
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 12 (1) , 1
Apraxia of Eyelid Opening and Blepharospasm in Two Spinocerebellar Ataxia Type 3 Patients
Neuroophthalmological phenotypical particularities of SCA3. Eyelid opening apraxia and asymmetrical blepharospasm. To illustrate the phenomenology for purposes of education.
- 17 January 2022
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 12 (1) , 1
Open AccessApraxia of Eyelid Opening and Blepharospasm in Two Spinocerebellar Ataxia Type 3 Patients
Neuroophthalmological phenotypical particularities of SCA3. Eyelid opening apraxia and asymmetrical blepharospasm. To illustrate the phenomenology for purposes of education.